SAN FRANCISCO – As Wall Street calmed in the wake of Alnylam Pharmaceuticals Inc.’s double shot of news – a $700 million expansion of the pact with Sanofi SA’s Genzyme unit, and the $175 million buyout of RNAi peer Sirna Therapeutics Inc. – investor eyes turned to the prospects of ALN-TTR-sc, the subcutaneous therapy targeting transthyretin (TTR), in Phase II trials for familial amyloid cardiomyopathy (FAC).